Anti-PD1 therapy was associated with higher rates of all-grade pneumonitis than PD-L1 therapy (40%; 95% CI: 32%–47% vs. 20.0%; 95% CI: 16%–24%). This evidence concerns the gene CD274 and pneumonitis.